Community screening and treatment of asymptomatic carriers of Plasmodium falciparum with artemether-lumefantrine to reduce malaria disease burden: a modelling and simulation analysis

BackgroundAsymptomatic carriers of Plasmodium falciparum serve as a reservoir of parasites for malaria transmission. Identification and treatment of asymptomatic carriers within a region may reduce the parasite reservoir and influence malaria transmission in that area.MethodsUsing computer simulation, this analysis explored the impact of community screening campaigns (CSC) followed by systematic treatment of P. falciparum asymptomatic carriers (AC) with artemether-lumefantrine (AL) on disease transmission. The model created by Okell et al (originally designed to explore the impact of the introduction of treatment with artemisinin-based combination therapy on malaria endemicity) was modified to represent CSC and treatment of AC with AL, with the addition of malaria vector seasonality. The age grouping, relative distribution of age in a region, and degree of heterogeneity in disease transmission were maintained. The number and frequency of CSC and their relative timing were explored in terms of their effect on malaria incidence. A sensitivity analysis was conducted to determine the factors with the greatest impact on the model predictions.ResultsThe simulation showed that the intervention that had the largest effect was performed in an area with high endemicity (entomological inoculation rate, EIR > 200); however, the rate of infection returned to its normal level in the subsequent year, unless the intervention was repeated. In areas with low disease burden (EIR < 10), the reduction was sustained for over three years after a single intervention. Three CSC scheduled in close succession (monthly intervals) at the start of the dry season had the greatest impact on the success of the intervention.ConclusionsCommunity screening and treatment of asymptomatic carriers with AL may reduce malaria transmission significantly. The initial level of disease intensity has the greatest impact on the potential magnitude and duration of malaria reduction. When combined with other interventions (e.g. long-lasting insecticide-treated nets, rapid diagnostic tests, prompt diagnosis and treatment, and, where appropriate, indoor residual spraying) the effect of this intervention can be sustained for many years, and it could become a tool to accelerate the reduction in transmission intensity to pre-elimination levels. Repeated interventions at least every other year may help to prolong the effect. The use of an effective diagnostic tool and a highly effective ACT, such as AL, is also vital. The modelling supports the evaluation of this approach in a prospective clinical trial to reduce the pool of infective vectors for malaria transmission in an area with marked seasonality.

[1]  R. Price,et al.  Effects of artemisinin derivatives on malaria transmissibility , 1996, The Lancet.

[2]  P. Milligan,et al.  Gametocytaemia after Drug Treatment of Asymptomatic Plasmodium falciparum , 2006, PLoS clinical trials.

[3]  C. Drakeley,et al.  Reduction of Malaria Transmission to Anopheles Mosquitoes with a Six-Dose Regimen of Co-Artemether , 2005, PLoS medicine.

[4]  S. Lindsay,et al.  The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[5]  Abdullah S Ali,et al.  Impact of Artemisinin-Based Combination Therapy and Insecticide-Treated Nets on Malaria Burden in Zanzibar , 2007, PLoS medicine.

[6]  J. Soto,et al.  Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study. , 2008, The American journal of tropical medicine and hygiene.

[7]  M. Appawu,et al.  Anaemia caused by asymptomatic Plasmodium falciparum infection in semi-immune African schoolchildren. , 1999, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[8]  David L. Smith,et al.  Optimally timing primaquine treatment to reduce Plasmodium falciparum transmission in low endemicity Thai-Myanmar border populations , 2009, Malaria Journal.

[9]  Renuka Kunte,et al.  WHO Guidelines for the treatment of malaria , 2011 .

[10]  A. Githeko,et al.  High prevalence of asymptomatic plasmodium falciparum infections in a highland area of western Kenya: a cohort study. , 2009, The Journal of infectious diseases.

[11]  Wes Hinsley,et al.  Reducing Plasmodium falciparum Malaria Transmission in Africa: A Model-Based Evaluation of Intervention Strategies , 2010, PLoS medicine.

[12]  Caroline O Buckee,et al.  Mathematical Models for a New Era of Malaria Eradication , 2008, PLoS medicine.

[13]  N. White,et al.  Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[14]  C. Karema,et al.  Malaria Journal BioMed Central , 2009 .

[15]  J. Sachs,et al.  The economic and social burden of malaria , 2002, Nature.

[16]  Margaret M. Dubeck,et al.  Improving educational achievement and anaemia of school children: design of a cluster randomised trial of school-based malaria prevention and enhanced literacy instruction in Kenya , 2010, Trials.

[17]  A. Ghani,et al.  Modelling the Impact of Artemisinin Combination Therapy and Long-Acting Treatments on Malaria Transmission Intensity , 2008, PLoS medicine.

[18]  S. Krudsood,et al.  A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. , 2001, The American journal of tropical medicine and hygiene.

[19]  N. White,et al.  Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. , 1999, The American journal of tropical medicine and hygiene.

[20]  S. Abdulla,et al.  Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial , 2008, The Lancet.

[21]  H. Babiker,et al.  A Randomized Open-Label Trial of Artesunate- Sulfadoxine-Pyrimethamine with or without Primaquine for Elimination of Sub-Microscopic P. falciparum Parasitaemia and Gametocyte Carriage in Eastern Sudan , 2007, PloS one.

[22]  N. White The role of anti-malarial drugs in eliminating malaria , 2008, Malaria Journal.

[23]  Z. Premji,et al.  Treatment of asymptomatic carriers with artemether-lumefantrine: an opportunity to reduce the burden of malaria? , 2010, Malaria Journal.

[24]  C. Hentschel The Medicines for Malaria Venture , 2002, Nature.